37 related articles for article (PubMed ID: 1522358)
1. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).
Penna GO; Pontes MAA; Talhari S; Gonçalves HS; Talhari C; Pessoa AS; Pedroza V; Bührer-Sékula S; Stefani MMA; Penna MLF
Braz J Infect Dis; 2024; 28(2):103745. PubMed ID: 38697216
[TBL] [Abstract][Full Text] [Related]
2. International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes.
Manickam P; Mehendale SM; Nagaraju B; Katoch K; Jamesh A; Kutaiyan R; Jianping S; Mugudalabetta S; Jadhav V; Rajkumar P; Padma J; Kaliaperumal K; Pannikar V; Krishnamurthy P; Gupte MD
Indian J Med Res; 2016 Oct; 144(4):525-535. PubMed ID: 28256460
[TBL] [Abstract][Full Text] [Related]
3. Description of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
Moura RS; Penna GO; Cardoso LP; de Andrade Pontes MA; Cruz R; de Sá Gonçalves H; Fernandes Penna ML; de Araújo Stefani MM; Bührer-Sékula S
Am J Trop Med Hyg; 2015 Jun; 92(6):1280-4. PubMed ID: 25940192
[TBL] [Abstract][Full Text] [Related]
4. Altered composition and functional profile of high-density lipoprotein in leprosy patients.
Lemes RMR; Silva CAME; Marques MÂM; Atella GC; Nery JADC; Nogueira MRS; Rosa PS; Soares CT; De P; Chatterjee D; Pessolani MCV; de Macedo CS
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008138. PubMed ID: 32226013
[TBL] [Abstract][Full Text] [Related]
5. Six months fixed duration multidrug therapy in paucibacillary leprosy: risk of relapse and disability in Agra PB cohort study.
Kumar A; Girdhar A; Girdhar BK
BMJ Open; 2012; 2(4):. PubMed ID: 22893667
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive insight into the anti-inflammatory properties of dapsone.
Khalilzadeh M; Shayan M; Jourian S; Rahimi M; Sheibani M; Dehpour AR
Naunyn Schmiedebergs Arch Pharmacol; 2022 Dec; 395(12):1509-1523. PubMed ID: 36125533
[TBL] [Abstract][Full Text] [Related]
7. Lack of Suspicion of Dapsone Hypersensitivity Syndrome in a Leprosy Patient: Case Report with Fatal Outcome.
Ansah R; Arkoh EA; Quao BO; Groger M
Res Rep Trop Med; 2023; 14():135-139. PubMed ID: 38170098
[TBL] [Abstract][Full Text] [Related]
8. Fixed-duration therapy in leprosy: limitations and opportunities.
Malathi M; Thappa DM
Indian J Dermatol; 2013 Mar; 58(2):93-100. PubMed ID: 23716796
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Treatment of Leprosy in Taiwan during the COVID-19 Pandemic: A Retrospective Study in a Tertiaty Center.
Hsieh CL; Hsiao PF
Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132239
[TBL] [Abstract][Full Text] [Related]
10. Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):371-8. PubMed ID: 10700910
[TBL] [Abstract][Full Text] [Related]
11. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
12. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
[TBL] [Abstract][Full Text] [Related]
13. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
[TBL] [Abstract][Full Text] [Related]
14. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
15. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
